Chemotherapy with Irinothecan, 5-Fluorouracil and Folinic Acid in the First-Line Management of Advanced Colorectal Carcinoma: Retrospective Study Academic Article uri icon


  • Colorectal cancer is one of the most common adult malignant tumors, affecting one person in twenty in the United States and in most developed countries. Although 40-50% of patients may be cured with surgery, many will develop metastatic disease 1. Until recently standard therapy for metastatic colorectal cancer was 5-fluorouracil (5-FU), commonly modulated by folinic acid (FA), which typically yielded a median survival time of 10-14 months 2. CPT-11 is a topoisomerase I inhibitor that has demonstrated antitumor activity against metastatic colorectal cancer when used alone as first-line treatment or as second-line treatment after the failure of 5-FU 3,4. In two recent phase III trials CPT-11 has also demonstrated its superiority in response rate and survival when administered as f irstl ine chemotherapy combined with 5-FU/FA when compared with 5-FU/FA alone 5,6. A European study compared the addition of CPT-11 to infusional 5FU/FA and an American study compared the addition of CPT-11 to the bolus 5-FU/FA regimen 5,6. We adopted the bolus regimen as the standard of care for the initial treatment of metastatic colorectal cancer. Here, we present our results with the Journal of Chemotherapy Vol. 15 n. 3 (304-305) 2003

publication date

  • January 1, 2003